Cell therapy is important in giving diagnostic and prognostic information for a variety of disorders, including HIV/AIDS, cancer, and infectious diseases. It helps academics and healthcare practitioners to acquire insights into disease causes, illness development, and therapy responses using novel cellular-based techniques. Global population expansion, climate change, and greater human-animal interaction have produced an environment conducive to the genesis of novel viral epidemics. Cell therapy research and applications are critical in tackling these issues because they provide enhanced diagnostic tools, therapeutic approaches, and a better knowledge of disease causes.
Cell biology research is primarily concerned with the development of novel medicines such as stem cell and gene therapies. High-quality tools, reagents, and associated goods are required for reliable findings. Meeting regulatory rules and maintaining demanding quality standards in cell biology research, on the other hand, comes at a considerable expense. This is a problem for institutes and small businesses with limited funds, as they may be unable to acquire pricey research products.
Precision medicine is a developing approach to illness treatment and prevention that takes into account genetic, environmental, and lifestyle factors. It entails selecting drugs for each patient depending on their individual condition and medical history. Oncology has made significant advances in precision medicine, even as its use expands to diverse disorders. This personalised approach to diagnosis, treatment, and prevention makes better judgements by utilising full patient information such as genetics, environment, and lifestyle.
The segmentation coverage of the study is provided below.
Cell Therapy Technologies Market based on Therapy Type
• Allogeneic Therapies
o Stem Cell Therapies
• Hematopoietic Stem Cell Therapies
• Mesenchymal Stem Cell Therapies
o Non-Stem Cell Therapies
• Keratinocytes & Fibroblast-based Therapies
• Others
• Autologous Therapies
o Stem Cell Therapies
• BM, Blood, & Umbilical Cord-derived Stem Cells
• Adipose derived cells
• Others
o Non-Stem Cell Therapies
• T-Cell Therapies
• CAR T Cell Therapy
• T Cell Receptor (TCR)-based
Cell Therapy Technologies Market based on Therapeutic Area
• Oncology
• Cardiovascular Disease (CVD)
• Musculoskeletal Disorders
• Dermatology
• Others
Cell Therapy Technologies Market based on Geography
• North America
o US
o Canada
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe (RoE)
• Asia Pacific (APAC)
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific (RoAPAC)
• Latin America (LATAM)
o Brazil
o Argentina
o Rest of South America
• Middle East and Africa (MEA)
o UAE
o Turkey
o Saudi Arabia
o South Africa
o Rest of Middle East & Africa
On the basis of cell type, the stem cell segment led the worldwide cell therapy market in 2019, and this trend is expected to continue during the forecast period, as they are gaining popularity as a result of different government initiatives. The number of stem cell banks is increasing in developing countries, which is fueling the expansion of the cell treatment industry. Furthermore, increased understanding of stem cell preservation has a beneficial impact on the cell treatment market growth. Furthermore, the allogenic treatment segment dominated the market in 2019. This therapy is favourable because it includes the generation of one's own immune stem cells, which can destroy cancer cells that survive treatment with high-dose cytotoxic medicines.
It is divided into two types of therapies: autologous and allogenic. The market is divided by therapeutic areas such as malignancies, musculoskeletal diseases, autoimmune disorders, dermatology, and others. It is divided into two types of end-users: hospitals and clinics and academic and research institutes. The market is divided into four regions: North America (the United States, Canada, and Mexico), Europe (Germany, the United Kingdom, France, Spain, Italy, and the rest of Europe), Asia-Pacific (Japan, China, India, Australia, and the rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and the rest of LAMEA).
The hospitals and clinics category is expected to develop at the fastest CAGR throughout the projection period. The segment's profitable expansion may be linked to an increase in the number of pipeline developments over the last few years. According to CRI, the number of cell therapy treatment projects climbed from 753 in 2018 to 1,011 in 2019.
Due to population growth, a growing geriatric population, and increased awareness among healthcare entities and patients about the potential of these therapies in chronic disease management, Asia-Pacific presents lucrative opportunities for key players operating in the cell therapy market. Furthermore, rising healthcare expenditures and the development of guidelines are projected to drive market expansion in the area.
Kolon Tissue Gene, Inc., Osiris Therapeutics, Inc., JCR Pharmaceuticals Co. Ltd., NuVasive, Inc., Stemedica Cell Technologies, Inc., Cells for Cells, Holostem Terapie Avanzate S.r.l., Mesoblast Ltd., and Medipost Co., Ltd. are among the leading companies operating in the global cell therapy market.
• This report illustrates the most vital attributes of the Cell Therapy Technologies Market, which are driving and providing opportunities.
• This research gives an in-depth analysis of the Cell Therapy Technologies Market growth on the basis of several segments in the market.
• This report presents the predictions of the past and present trends of the Cell Therapy Technologies Market.
• This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Cell Therapy Technologies Market.
Table of Contents 1. Executive Summary 2. Industry Outlook 2.1. Industry Overview 2.2. Industry Trends 3. Market Snapshot 3.1. Market Definition 3.2. Market Outlook 3.2.1. Porter Five Forces 3.3. Related Markets 4. Market characteristics 4.1. Market Overview 4.2. Market Segmentation 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. DRO - Impact Analysis 5. Therapy Type: Market Size & Analysis 5.1. Overview 5.2. Allogeneic Therapies 5.3. Autologous Therapies 6. Therapeutic Area: Market Size & Analysis 6.1. Overview 6.2. Oncology 6.3. Cardiovascular Disease (CVD) 6.4. Musculoskeletal Disorders 6.5. Dermatology 6.6. Others 7. Geography: Market Size & Analysis 7.1. Overview 7.2. North America (U.S., Mexico, Canada) 7.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe) 7.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC) 7.5. Latin America (Brazil, Argentina) 7.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa) 8. Competitive Landscape 8.1. Competitor Comparison Analysis 8.2. Market Developments 8.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships 8.2.2. Product Launches and execution 9. Vendor Profiles 9.1. Novartis AG 9.1.1. Overview 9.1.2. Financial Overview 9.1.3. Product Offerings 9.1.4. Developments 9.1.5. Business Strategy 9.2. Gilead Sciences, Inc. 9.2.1. Overview 9.2.2. Financial Overview 9.2.3. Product Offerings 9.2.4. Developments 9.2.5. Business Strategy 9.3. Bristol-Myers Squibb Company 9.3.1. Overview 9.3.2. Financial Overview 9.3.3. Product Offerings 9.3.4. Developments 9.3.5. Business Strategy 9.4. Johnson & Johnson Services, Inc 9.4.1. Overview 9.4.2. Financial Overview 9.4.3. Product Offerings 9.4.4. Developments 9.4.5. Business Strategy 9.5. JCR Pharmaceuticals Co., Ltd. 9.5.1. Overview 9.5.2. Financial Overview 9.5.3. Product Offerings 9.5.4. Developments 9.5.5. Business Strategy 9.6. Tego Science 9.6.1. Overview 9.6.2. Financial Overview 9.6.3. Product Offerings 9.6.4. Developments 9.6.5. Business Strategy 9.7. Atara Biotherapeutics 9.7.1. Overview 9.7.2. Financial Overview 9.7.3. Product Offerings 9.7.4. Developments 9.7.5. Business Strategy 9.8. Takeda Pharmaceutical Company Limited 9.8.1. Overview 9.8.2. Financial Overview 9.8.3. Product Offerings 9.8.4. Developments 9.8.5. Business Strategy 9.9. Bluebird Bio, Inc. 9.9.1. Overview 9.9.2. Financial Overview 9.9.3. Product Offerings 9.9.4. Developments 9.9.5. Business Strategy 9.10. Dendreon Corp. 9.10.1. Overview 9.10.2. Financial Overview 9.10.3. Product Offerings 9.10.4. Developments 9.10.5. Business Strategy 10. Analyst Opinion 11. Annexure 11.1. Report Scope 11.2. Market Definitions 11.3. Research Methodology 11.3.1. Data Collation and In-house Estimation 11.3.2. Market Triangulation 11.3.3. Forecasting 11.4. Report Assumptions 11.5. Declarations 11.6. Stakeholders 11.7. Abbreviations
Tables TABLE 1. CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 2. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR ALLOGENEIC THERAPIES, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 3. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR AUTOLOGOUS THERAPIES, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 4. CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 5. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 6. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR CARDIOVASCULAR DISEASE (CVD), BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 7. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR MUSCULOSKELETAL DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 8. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR DERMATOLOGY,2021-2030 (USD BILLION) TABLE 9. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 10. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) TABLE 11. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 12. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 13. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 14. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 15. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 16. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 17. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 18. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 19. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 20. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 21. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 22. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 23. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) TABLE 24. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 25. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 26. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 27. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 28. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 29. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 30. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 31. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 32. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 33. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 34. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 35. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 36. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 37. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 38. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 39. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 40. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 41. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 42. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 43. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 44. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 45. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) TABLE 46. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 47. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 48. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 49. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 50. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 51. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 52. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 53. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 54. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 55. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 56. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 57. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 58. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 59. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 60. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 61. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 62. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 63. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 64. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 65. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 66. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 67. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 68. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 69. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 70. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 71. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 72. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 73. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 74. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 75. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 76. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 77. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 78. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 79. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 80. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 81. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 82. NOVARTIS AG: FINANCIALS TABLE 83. NOVARTIS AG: PRODUCTS & SERVICES TABLE 84. NOVARTIS AG: RECENT DEVELOPMENTS TABLE 85. GILEAD SCIENCES, INC.: FINANCIALS TABLE 86. GILEAD SCIENCES, INC.: PRODUCTS & SERVICES TABLE 87. GILEAD SCIENCES, INC.: RECENT DEVELOPMENTS TABLE 88. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS TABLE 89. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES TABLE 90. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS TABLE 91. JOHNSON & JOHNSON SERVICES, INC: FINANCIALS TABLE 92. JOHNSON & JOHNSON SERVICES, INC: PRODUCTS & SERVICES TABLE 93. JOHNSON & JOHNSON SERVICES, INC: RECENT DEVELOPMENTS TABLE 94. JCR PHARMACEUTICALS CO., LTD.: FINANCIALS TABLE 95. JCR PHARMACEUTICALS CO., LTD.: PRODUCTS & SERVICES TABLE 96. JCR PHARMACEUTICALS CO., LTD.: RECENT DEVELOPMENTS TABLE 97. TEGO SCIENCE: FINANCIALS TABLE 98. TEGO SCIENCE: PRODUCTS & SERVICES TABLE 99. TEGO SCIENCE: RECENT DEVELOPMENTS TABLE 100. ATARA BIOTHERAPEUTICS: FINANCIALS TABLE 101. ATARA BIOTHERAPEUTICS: PRODUCTS & SERVICES TABLE 102. ATARA BIOTHERAPEUTICS: DEVELOPMENTS TABLE 103. TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIALS TABLE 104. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS & SERVICES TABLE 105. TAKEDA PHARMACEUTICAL COMPANY LIMITED: RECENT DEVELOPMENTS TABLE 106. BLUEBIRD BIO, INC.: FINANCIALS TABLE 107. BLUEBIRD BIO, INC.: PRODUCTS & SERVICES TABLE 108. BLUEBIRD BIO, INC.: RECENT DEVELOPMENTS TABLE 109. DENDREON CORP.: FINANCIALS TABLE 110. DENDREON CORP.: PRODUCTS & SERVICES TABLE 111. DENDREON CORP.: RECENT DEVELOPMENTS Charts CHART. 1. CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 2. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR ALLOGENEIC THERAPIES, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 3. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR AUTOLOGOUS THERAPIES, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 4. CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 5. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 6. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR CARDIOVASCULAR DISEASE (CVD), BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 7. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR MUSCULOSKELETAL DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 8. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR DERMATOLOGY,2021-2030 (USD BILLION) CHART. 9. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 10. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) CHART. 11. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 12. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 13. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) CHART. 14. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 15. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 16. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) CHART. 17. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 18. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 19. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) CHART. 20. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 21. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 22. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) CHART. 23. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) CHART. 24. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 25. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 26. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) CHART. 27. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 28. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 29. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) CHART. 30. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 31. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 32. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) CHART. 33. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 34. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 35. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) CHART. 36. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 37. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 38. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) CHART. 39. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 40. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 41. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) CHART. 42. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 43. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 44. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) CHART. 45. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) CHART. 46. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 47. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 48. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) CHART. 49. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 50. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 51. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) CHART. 52. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 53. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 54. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) CHART. 55. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 56. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 57. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) CHART. 58. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 59. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 60. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) CHART. 61. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 62. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 63. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) CHART. 64. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 65. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 66. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) CHART. 67. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 68. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 69. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) CHART. 70. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 71. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 72. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) CHART. 73. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 74. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 75. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) CHART. 76. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 77. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 78. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) CHART. 79. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) CHART. 80. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) CHART. 81. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) CHART. 82. NOVARTIS AG: FINANCIALS CHART. 83. NOVARTIS AG: PRODUCTS & SERVICES CHART. 84. NOVARTIS AG: RECENT DEVELOPMENTS CHART. 85. GILEAD SCIENCES, INC.: FINANCIALS CHART. 86. GILEAD SCIENCES, INC.: PRODUCTS & SERVICES CHART. 87. GILEAD SCIENCES, INC.: RECENT DEVELOPMENTS CHART. 88. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS CHART. 89. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES CHART. 90. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS CHART. 91. JOHNSON & JOHNSON SERVICES, INC: FINANCIALS CHART. 92. JOHNSON & JOHNSON SERVICES, INC: PRODUCTS & SERVICES CHART. 93. JOHNSON & JOHNSON SERVICES, INC: RECENT DEVELOPMENTS CHART. 94. JCR PHARMACEUTICALS CO., LTD.: FINANCIALS CHART. 95. JCR PHARMACEUTICALS CO., LTD.: PRODUCTS & SERVICES CHART. 96. JCR PHARMACEUTICALS CO., LTD.: RECENT DEVELOPMENTS CHART. 97. TEGO SCIENCE: FINANCIALS CHART. 98. TEGO SCIENCE: PRODUCTS & SERVICES CHART. 99. TEGO SCIENCE: RECENT DEVELOPMENTS CHART. 100. ATARA BIOTHERAPEUTICS: FINANCIALS CHART. 101. ATARA BIOTHERAPEUTICS: PRODUCTS & SERVICES CHART. 102. ATARA BIOTHERAPEUTICS: DEVELOPMENTS CHART. 103. TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIALS CHART. 104. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS & SERVICES CHART. 105. TAKEDA PHARMACEUTICAL COMPANY LIMITED: RECENT DEVELOPMENTS CHART. 106. BLUEBIRD BIO, INC.: FINANCIALS CHART. 107. BLUEBIRD BIO, INC.: PRODUCTS & SERVICES CHART. 108. BLUEBIRD BIO, INC.: RECENT DEVELOPMENTS CHART. 109. DENDREON CORP.: FINANCIALS CHART. 110. DENDREON CORP.: PRODUCTS & SERVICES CHART. 111. DENDREON CORP.: RECENT DEVELOPMENTS
Publisher: IHR Insights
Related Reports
- Global Epilepsy Therapeutics Market (2024 Edition): Analysis By Generation (First Generation, Second Generation, Third Generation), By Route of Administration, By Type, By Region, By Country: Market Insights and Forecast (2020-2030)
- Global Online Pharmacy Market (2024 Edition): Analysis By Drug Type (Over the Counter (OTC) Drugs, Prescription Drugs, Others), By Platform, By Product Type, By Region: Market Insights and Forecast (2020-2030)
- Global Diagnostic X-rays Market (2024 Edition): Analysis By Type (General Radiography, Angiography, Surgical Fluoroscopy, Mobile X ray, Other Types), By End Users, By Region, By Country: Market Insights and Forecast (2020-2030)
- Global Diagnostic Labs Market (2024 Edition): Analysis By Testing Services (Physiological Function Testing, General and Clinical Testing, Esoteric Testing, Specialized Testing, and Others), By Lab Type, By Application: Market Insights and Forecast (2020-2030)
- Lateral Flow Assays Market By Product Type (Lateral Flow Readers {Digital/Mobile Readers and Benchtop Readers} and Kits and Reagents), By Application (Clinical Testing {Pregnancy Testing, Influenza Testing, Tuberculosis, D-Dimer Testing, and Other Clinical Testing}, Drug Abuse Testing, Veterinary Diagnostics, Food Safety & Environmental Testing, and Other Applications), By Technique (Sandwich Assay, Competitive Assay, and Multiplex Assay), By End-User (Home Care, Hospitals and Clinics, and Other End Users), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 - 2035
Why Market Study Report?
- Best Price for Reports
- Large Report Database
- Easily Customize Reports
- 24/7 Email & Phone Support